Can Autoimmune Encephalitis Be Better Treated Today?
Autoimmune encephalitis are rare diseases where the immune system mistakenly attacks proteins in the brain. Over the past twenty years, researchers have identified more than twenty types of encephalitis linked to specific antibodies, each causing distinct symptoms such as memory disorders, epileptic seizures, or behavioral changes. Although these diseases are now better understood, their treatment remains a challenge due to the lack of robust clinical trials. Physicians therefore rely on observational studies and expert recommendations to choose the best approaches.
Current treatment is based on three pillars: immunotherapy to calm the immune response, removal of triggers such as tumors when present, and management of symptoms such as seizures or psychiatric disorders. First-line treatments include high-dose corticosteroids, plasma exchange, or intravenous immunoglobulins. These methods often lead to rapid improvement, especially if initiated early. However, their effectiveness varies depending on the type of encephalitis and individual response.
For resistant cases, second-line therapies such as rituximab or cyclophosphamide are used. These drugs specifically target the immune cells responsible for attacking the brain. Rituximab, for example, significantly reduces the risk of relapse in some patients. Third-line treatments, still under development, explore new targets such as cytokines or plasma cells, but their use remains limited to specific cases due to their complexity and potential side effects.
Despite these advances, challenges remain. The optimal duration of immunosuppressive treatment, relapse prevention, and the identification of biological markers to personalize care are still open questions. Patients and their loved ones face a heavy burden: cognitive sequelae, persistent fatigue, and social difficulties. Many do not return to their previous quality of life, highlighting the importance of multidisciplinary support and long-term care.
Current research is also exploring innovative approaches, such as cellular therapies targeting B lymphocytes or specific antibodies. These avenues could, in the future, offer more precise and less invasive solutions. In the meantime, the management of autoimmune encephalitis requires close collaboration between neurologists, psychiatrists, and rehabilitation specialists to improve the quality of life for patients and their caregivers.
Site Sources
Official Study Source
DOI: https://doi.org/10.1007/s12325-026-03513-7
Title: The Treatment of Antibody-Mediated Encephalitis: Current, Future Therapies, Unmet Need and Patient Management
Journal: Advances in Therapy
Publisher: Springer Science and Business Media LLC
Authors: Smaila Mulic-Al Bunni; Markus Gschwind; Sebastian Finkener; Adam Al-Diwani; Ava Easton; Adam E. Handel; Sophie N. M. Binks